Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
For phase Ib: To determine the maximum-tolerated dose (MTD) / recommended Phase II dose (RP2D) of buparlisib when administered orally in combination with every-3-week administration of docetaxel to adult patients with Stage IIIb or Stage IV NSCLC of squamous histology previously treated with platinum-based chemotherapy For phase II: To estimate the treatment effect of every-three-week administration of docetaxel and daily buparlisib or placebo on PFS in patients previously treated with platinum-based chemotherapy for advanced or metastatic squamous NSCLC
Critère d'inclusion
- advanced/metastatic squamous non small cell lung cancer